ClinicalTrials.gg
CompletedNCT06131437Updated Feb 6, 2026

A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

A Phase 3 interventional study of Cagrilintide and Semaglutide in Obesity, sponsored by Novo Nordisk A/S. Completed at 46 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
809
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing cagrilintide in Obesity — 9 open to participants now, 15 under way, 9 of them phase 3. cagrilintide · Obesity.

Enrollment
5th of 36
809 · median 154
Started
2023
with 4 others
Phase 3
15 of 36
4 open now
Registered
14th of 36
by date
Lead sponsor
36 of 36
Novo Nordisk A/S

Among the 36 studies testing cagrilintide in Obesity, this one is the 5th largest by enrollment, is one of 5 that started in 2023, is one of 15 in phase 3, and was the 14th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

9 of the 36 studies testing cagrilintide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About cagrilintide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing cagrilintide in Obesity, or all of them as a file.
02

Study summary

This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide. CagriSema is not yet being prescribed by doctors. Participant will get injections once a week throughout the treatment period. Participant will inject the study medicine under the skin with a pen injector in the thigh, stomach, or upper arm. After a first low dose, the study medicine will be gradually increased until reaching the planned dose (2.4 mg CagriSema or 15 mg Tirzepatide). The study will last for about one and a half year for each participant.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female
  • Age 18 years or above at the time of signing the
  • (BMI) of ≥ 30.0 kilogram per square meter (kg/m\^2)

Exclusion criteria

Exclusion Criteria:

  • (HbA1c) ≥ 6.5 % (48 millimoles per mole [mmol/mol]) as measured by the central laboratory at screening
  • History of type 1 or type 2 diabetes mellitus
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
809 participants (actual)

Study arms

  • Experimental
    CagriSema 2.4 mg/2.4 mg

    Participants will receive 2.4 mg cagrilintide and 2.4 mg semaglutide subcutaneously once-weekly (dose escalation period of 16 weeks) for up to 84 weeks.

    Drug: Cagrilintide · Drug: Semaglutide

  • Active comparator
    Tirzepatide 15 mg

    Participants will receive 15 mg tirzepatide subcutaneously once-weekly (dose escalation period of 20 weeks) for up to 84 weeks.

    Drug: Tirzepatide

Interventions

  • Cagrilintide will be administered subcutaneously.

  • Semaglutide will be administered subcutaneously.

  • Tirzepatide will be administered subcutaneously.

06

What researchers measure

Primary outcomes

  1. To confirm non-inferiority of CagriSema versus tirzepatide: Relative change in body weight

    Measured in percentage (%).

    Time frame: From baseline (week 0) to end of treatment (week 84)

Secondary outcomes

  1. To confirm superiority of CagriSema versus tirzepatide: Relative change in body weight

    Measured in percentage (%).

    Time frame: From baseline (week 0) to end of treatment (week 84)

  2. Achievement of greater than or equal to (≥) 25% weight reduction

    Count of participants.

    Time frame: From baseline (week 0) to end of treatment (week 84)

  3. Achievement of ≥ 30% weight reduction

    Count of participants.

    Time frame: From baseline (week 0) to end of treatment (week 84)

  4. Change in waist circumference

    Measured in centimeter (cm).

    Time frame: From baseline (week 0) to end of treatment (week 84)

  5. Change in systolic blood pressure (SBP)

    Measured in millimeter of mercury (mmHg).

    Time frame: From baseline (week 0) to end of treatment (week 84)

  6. Change in diastolic blood pressure (DBP)

    Measured in mmHg.

    Time frame: From baseline (week 0) to end of treatment (week 84)

  7. Relative change in lipids: Total cholesterol

    Measured in percentage.

    Time frame: From baseline (week 0) to end of treatment (week 84)

  8. Relative change in lipids: High-density lipoprotein (HDL) cholesterol

    Measured in percentage.

    Time frame: From baseline (week 0) to end of treatment (week 84)

  9. Relative change in lipids: Non-HDL cholesterol

    Measured in percentage.

    Time frame: From baseline (week 0) to end of treatment (week 84)

  10. Relative change in lipids: Low-density lipoprotein (LDL) cholesterol

    Measured in percentage.

    Time frame: From baseline (week 0) to end of treatment (week 84)

  11. Relative change in lipids: Very low-density lipoprotein (VLDL) cholesterol

    Measured in percentage.

    Time frame: From baseline (week 0) to end of treatment (week 84)

  12. Relative change in lipids: Triglycerides

    Measured in percentage.

    Time frame: From baseline (week 0) to end of treatment (week 84)

  13. Number of Treatment-emergent Adverse Events (TEAEs)

    Count of events.

    Time frame: From baseline (week 0) to end of study (week 90)

  14. Number of Treatment Emergent Serious adverse events (TESAEs)

    Count of events.

    Time frame: From baseline (week 0) to end of study (week 90)

07

Study locations

46 sites
  • Univ of Alabama Birmingham
    Birmingham, Alabama 35294, United States
  • Chambliss Clinical Trials LLC
    Montgomery, Alabama 36106, United States
  • FDRC
    Costa Mesa, California 92627, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Univ of Colorado at Denver
    Aurora, Colorado 80045, United States
  • Yale University School Of Medicine
    New Haven, Connecticut 06519, United States
  • Northeast Research Institute
    Fleming Island, Florida 32003, United States
  • Jacksonville Ctr For Clin Res
    Jacksonville, Florida 32216, United States
  • South Broward Research LLC
    Miramar, Florida 33027, United States
  • Hope Clin Res & Wellness
    Conyers, Georgia 30094, United States
  • East West Med Res Inst
    Honolulu, Hawaii 96814, United States
  • Great Lakes Clinical Trials
    Chicago, Illinois 60640, United States
  • Endeavor Health
    Skokie, Illinois 60077, United States
  • Evanston Premier Hlthcr Res
    Skokie, Illinois 60077, United States
  • Midwest Inst For Clin Res
    Indianapolis, Indiana 46260, United States
  • Northern Pines Hlth Ctr, PC
    Buckley, Michigan 49620, United States
  • StudyMetrix Research LLC
    City of Saint Peters, Missouri 63303, United States
  • Comprehensive Weight Ctrl Prog
    New York, New York 10021, United States
  • University of North Carolina
    Chapel Hill, North Carolina 27514, United States
  • Medication Mgmnt, LLC_Grnsboro
    Greensboro, North Carolina 27405, United States
  • PharmQuest Life Sciences LLC
    Greensboro, North Carolina 27408, United States
  • Accellacare_NC
    Raleigh, North Carolina 27609, United States
  • Accellacare
    Wilmington, North Carolina 28401, United States
  • New Venture Medical Research
    Wadsworth, Ohio 44281, United States
  • Lynn Institute of Norman
    Norman, Oklahoma 73072, United States
  • The University of Penn Center
    Philadelphia, Pennsylvania 19104-3317, United States
  • Clinical Res Collaborative
    Cumberland, Rhode Island 02864, United States
  • Medical University Of South Carolina
    Charleston, South Carolina 29425, United States
  • Coastal Carolina Res Ctr
    North Charleston, South Carolina 29405, United States
  • Hillcrest Clinical Research
    Simpsonville, South Carolina 29681-1538, United States
  • Spartanburg Medical Research
    Spartanburg, South Carolina 29303, United States
  • Holston Medical Group_Bristol
    Bristol, Tennessee 37620, United States
  • Holston Medical Group
    Kingsport, Tennessee 37660, United States
  • Amarillo Med Spec LLP
    Amarillo, Texas 79124, United States
  • Elligo Clin Res Centre
    Austin, Texas 78704, United States
  • UT Health University of Texas
    Bellaire, Texas 77401, United States
  • Baylr Sctt White Rs Inst, Endo
    Dallas, Texas 75226, United States
  • Velocity Clin Res, Dallas
    Dallas, Texas 75230, United States
  • UT Southwestern Medical Center-CRU
    Dallas, Texas 75390, United States
  • DCOL Ctr for Clin Res
    Longview, Texas 75605, United States
  • Washington Cntr Weight Mgmt
    Arlington, Virginia 22206, United States
  • Health Res of Hampton Roads
    Newport News, Virginia 23606, United States
  • National Clin Res Inc.
    Richmond, Virginia 23294, United States
  • Selma Medical Associates
    Winchester, Virginia 22601-3834, United States
  • Capital Clin Res Ctr,LLC
    Olympia, Washington 98502, United States
  • Rainier Clin Res Ctr Inc
    Renton, Washington 98057, United States
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Dec 2025, 24 months.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 24 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2023
First posted
Nov 14, 2023
StartActual
Nov 27, 2023
Primary completionActual
Dec 8, 2025
CompletionActual
Jan 9, 2026
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06131437
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Nov 14, 2023
Start date
Nov 27, 2023
Primary completion
Dec 8, 2025
Completion
Jan 9, 2026
Last update
Feb 6, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cagrilintide

Start the discussion